ANNEL A - 3

ANGOLA

Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Angola

2. Grant number: 1518-AGO-25c-X

3. Date of Decision Letter: 27 February 2017

4. Date of the Partnership Framework Agreement: 04 October 2013

5. Programme title: New Vaccine Support (NVS), IPV routine

6. Vaccine type: Inactivated Polio Vaccine (IPV)

7. Requested product presentation and formulation of vaccine:\footnote{1} Inactivated Polio Vaccine, 10 doses per vial, LIQUID

8. Programme duration\footnote{2}: 2015 – 2018

9. Programme Budget (indicative):
   \textit{Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi’s review and approval processes.}

   \begin{center}
   \begin{tabular}{|c|c|c|}
   \hline
   Programme Budget (US$) & 2015-2016 & 2017 & Total\footnote{3} \\
   \hline
   129,053 & 332,500 & 461,553 & \\
   \hline
   \end{tabular}
   \end{center}

10. Vaccine introduction grant: $785,500 was disbursed on 6 July 2015 as per the decision letter dated 4 February 2015

11. Indicative Annual Amounts:\footnote{4}

   \begin{center}
   \begin{tabular}{|l|c|}
   \hline
   Type of supplies to be purchased with Gavi funds in each year & 2017 \\
   \hline
   Number of IPV vaccines doses & 371,100 \\
   \hline
   Annual Amounts (US$) & 332,500 \\
   \hline
   \end{tabular}
   \end{center}

12. Procurement agency: UNICEF

\footnotetext{1}{Please refer to section 18 for additional information on IPV presentation.}
\footnotetext{2}{This is the entire duration of the Programme.}
\footnotetext{3}{This is the total amount endorsed by Gavi for 2015 to 2017.}
\footnotetext{4}{This is the amount that Gavi has approved.
13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable
   Gavi’s usual co-financing requirements do not apply to IPV. However, Angola
   is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angola shall submit the following information in May: number of children to be vaccinated,</td>
<td>15 May 2017</td>
</tr>
<tr>
<td>vaccine stock levels including buffer stock, wastage rates, any proposed changes in</td>
<td></td>
</tr>
<tr>
<td>presentation or minimum co-financing levels and vaccines received.</td>
<td></td>
</tr>
</tbody>
</table>

   | In accordance with applicable Gavi processes, Country shall report on programmatic and       | To be agreed with  |
   | financial performance.                                                                      | Secretariat        |

17. Financial clarifications: Not applicable

18. Other conditions:

   Due to unprecedented demand for IPV and the challenges to scale up production
   capacities, the global IPV supply is highly constrained and is unlikely to meet all country
   requirements in the short term. As a consequence, the actual number of doses shipped
   may differ from the amounts specified in this Decision Letter. In order to mitigate these
   circumstances, you are strongly encouraged to optimally manage available supply and
   follow recommendations and guidelines from WHO and UNICEF to reduce vaccine
   wastage.

   If Angola envisages a switch in product presentation, it is encouraged to incorporate
   elements for both IPV presentations in your initial introduction preparations, in order to
   minimise the need for later interventions and facilitate the switch. In those circumstances,
   in principle, no product switch grant will be provided to Angola.

On behalf of Gavi
Signed by

Hind Khatib-Othman
Managing Director, Country Programmes
27 February 2017